TNFR1產(chǎn)品信息
英文名稱：Tumor necrosis factor receptor superfamily member 1A
中文名稱：腫瘤壞死因子受體1型
靶點別稱：TNFR1,CD120a,TNFRSF1A,TBP1,TNF-R,TNF-R-I,TNF-R55,TNFAR,TNFR55,TNFR60
物種：Human
屬性：Protein
標記：Unconjugated
內(nèi)毒素（Endotoxin）
Less than 1.0 EU per μg by the LAL method.
純度（Purity）
>98% as determined by SDS-PAGE.
制劑（Formulation）
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
重構(gòu)方法（Reconstitution）
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存儲（Storage）
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
1. -20°C to -70°C for 12 months in lyophilized state;
2. -70°C for 3 months under sterile conditions after reconstitution.
TNFR1分子背景
Tumor necrosis factor receptor 1 (TNF-R1) is also known as Tumor necrosis factor receptor superfamily member 1A (TNFRSF1A), TNFAR, CD antigen CD120a, which belongs to the tumor necrosis factor receptor superfamily. TNF-R1 contains one death domain and four TNFR-Cys repeats. TNF-R1 is the receptor of TNFSF2 / TNF-alpha and homotrimeric TNFSF1 / lymphotoxin - alpha. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. TNF-R1 contributes to the induction of non - cytocidal TNF effects including anti-viral state and activation of the acid sphingomyelinase. Defects in TNFRSF1A are the cause of familial hibernian fever (FHF).
TNFR1用戶評價
關(guān)鍵字： TNFR1;TNFR1蛋白;腫瘤壞死因子受體1型;CD120a;TNFRSF1A;
百普賽斯集團ACROBiosystems Group（股票代碼：301080）是成立于2010年的跨國生物科技公司，是為全球生物醫(yī)藥、健康產(chǎn)業(yè)領(lǐng)域提供關(guān)鍵生物試劑產(chǎn)品及解決方案的行業(yè)平臺型基石企業(yè)。2021年在創(chuàng)業(yè)板上市。百普賽斯集團業(yè)務(wù)遍布全球，橫跨亞洲、北美洲、歐洲，在中國、美國、瑞士等12個城市設(shè)有辦公室、研發(fā)中心及生產(chǎn)基地。目前累計服務(wù)客戶超6000家，與全球Top 20醫(yī)藥企業(yè)均建立了長期、穩(wěn)定的合作伙伴關(guān)系。集團旗下?lián)碛衅放艫CROBiosystems百普賽斯、bioSeedin柏思薈、Condense Capital墾拓資本和ACRODiagnostics百斯醫(yī)學(xué)等。